australia


Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists

February 3rd, 2023 - Ryan Allway

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.   The Therapeutic Goods Administration (TGA) will permit the prescribing of MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression. These are […]

ZYUS Life Sciences Ships Medical Cannabinoid Oil Formulations for Distribution in Australia

July 19th, 2022 - Ryan Allway

Shipment marks an important milestone to enable patients in Australia to access ZYUS’ medical cannabinoid oil formulations as part of strategic international expansion   SASKATOON, Saskatchewan, July 19, 2022–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”), a Canadian life sciences company leading scientific research and development in phyto-therapeutics, has completed its first international shipment of ZYUS’ first-generation […]

PharmAla Biotech to supply Mind Medicine Australia with GMP MDMA for Clinical Trial

April 11th, 2022 - Ryan Allway

PharmAla’s GMP MDMA will accelerate trial work funded by Australia’s premier Psychedelics charity PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for Mind Medicine Australia. Mind Medicine Australia’s order will be available for delivery later this year, for use in an ethics approved healthy persons trial and will be subject […]

SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders

January 4th, 2022 - Ryan Allway

  Patent Extends Protection for its Novel Compounds and Methods Already granted in Australia and Japan   TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), marks today one of the […]

MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial

October 13th, 2021 - Ryan Allway

Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression   VANCOUVER, BC, Oct. 13, 2021 /CNW/ – MYND Diagnostics Inc., a wholly-owned subsidiary of MYND Life Sciences (CSE: MYND) (OTC: MYNDF) is pleased to announce that the Company’s proprietary biomarker test technology will be a pivotal component of a proposed clinical trial seeking partial funds from a $15 million fund […]

SciSparc Awarded Three Patents For Its Novel Compounds and Methods

September 7th, 2021 - Ryan Allway

TEL AVIV, Israel, Sept. 7, 2021 /PRNewswire/ — SciSparc Ltd. (OTC Pink: SPRCF), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company”), today announced it has been awarded two patents from the Australian Patent Office and one from the Japanese Patent Office concerning the proprietary […]

Flora Growth Executes International Sales Agreement to Enter Australian Medical Cannabis and Over-The-Counter CBD Market

July 29th, 2021 - Ryan Allway

Flora signs Letter of Intent with an international distributor based in Australia to provide raw and finished medical cannabis products for medical cannabis patients Recent Colombian legislative update allows for the sale and export of raw cannabis materials, namely dried flower, in addition to derivatives, to international markets Australian medical cannabis market estimated to surpass AU$200 million […]

Little Green Pharma To Accelerate Growth Strategy With Acquisition of World-Class Production and Manufacturing Facility in Denmark

June 22nd, 2021 - Ryan Allway

PERTH, Australia, June 22, 2021 /PRNewswire/ — Little Green Pharma Ltd (ASX: LGP) has acquired a world-class, fully-operational, GMP medicinal cannabis cultivation and manufacturing facility in Denmark from Canopy Growth Corporation (TSX:WEED, NASDAQ: CGC).   The facility, located in Northern Odense, has the capacity to produce in excess of 12 tonnes per annum of finished flower and provides LGP with much-needed product supply from […]

ZYUS Life Sciences Increases Global Patient Access to Medical Cannabinoids in Australia with Health House International Sales and Distribution Agreement

April 28th, 2021 - Ryan Allway

New agreement will enable patients in Australia to access ZYUS’ cannabinoid formulations as part of international expansion   SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”), a Canadian life sciences company leading scientific research and development in phyto-therapeutics, is pleased to announce that it has entered a new non-exclusive, multiyear agreement with Australian medical cannabis importer, […]

Subversive Acquisition LP Announces InterCure’s Letter of Intent Relating to the Acquisition of a Multi-National Medical Cannabis Producer, Better Holdings

April 5th, 2021 - Ryan Allway

InterCure Signs Letter of Intent with Cann Pharmaceutical Ltd. Acquisition Strengthens InterCure’s Position as the Largest Cannabis Company Outside of North America TORONTO, April 05, 2021 (GLOBE NEWSWIRE) — SUBVERSIVE ACQUISITION LP (TSX: SVX.U, NEO: SVX.U, OTCQX: SBVRF) (“SVX”) announced today that InterCure Ltd. (dba Canndoc) (TASE: INCR) (“InterCure”), Israel’s leading cannabis company and SVX’s intended target […]

Subversive Acquisition LP Announces InterCure’s Letter of Intent Relating to the Acquisition of a Multi-National Medical Cannabis Producer, Better Holdings

April 5th, 2021 - Ryan Allway

InterCure Signs Letter of Intent with Cann Pharmaceutical Ltd. Acquisition Strengthens InterCure’s Position as the Largest Cannabis Company Outside of North America TORONTO, April 05, 2021 (GLOBE NEWSWIRE) — SUBVERSIVE ACQUISITION LP (TSX: SVX.U, NEO: SVX.U, OTCQX: SBVRF) (“SVX”) announced today that InterCure Ltd. (dba Canndoc) (TASE: INCR) (“InterCure”), Israel’s leading cannabis company and SVX’s intended target […]

Creso Pharma Gears Up for Adult-Use Market with New Supply Agreement

January 23rd, 2019 - Ryan Allway

Canada’s cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte analysts, driven by the legalization of adult-use cannabis in October of last year. While many licensed producers have been scaling up their production, the market continues to experience a shortfall in supply that has created an opportunity for investors […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading